Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Other Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - Net
Ratios

Dr Reddys Laboratories (RDY) Receivables Refunds (2017 - 2023)

Dr Reddys Laboratories has reported Receivables Refunds over the past 7 years, most recently at $32.7 million for Q1 2023.

  • For Q1 2023, Receivables Refunds fell 39.09% year-over-year to $32.7 million; the TTM value through Mar 2023 reached $32.7 million, down 39.09%, while the annual FY2023 figure was $33.0 million, 37.74% down from the prior year.
  • Receivables Refunds for Q1 2023 was $32.7 million at Dr Reddys Laboratories, down from $53.7 million in the prior quarter.
  • Over five years, Receivables Refunds peaked at $60.4 million in Q1 2020 and troughed at $32.7 million in Q1 2023.
  • A 5-year average of $46.5 million and a median of $48.2 million in 2019 define the central range for Receivables Refunds.
  • Biggest five-year swings in Receivables Refunds: soared 42.54% in 2022 and later plummeted 39.09% in 2023.
  • Year by year, Receivables Refunds stood at $48.2 million in 2019, then grew by 25.42% to $60.4 million in 2020, then crashed by 37.72% to $37.6 million in 2021, then skyrocketed by 42.54% to $53.7 million in 2022, then crashed by 39.09% to $32.7 million in 2023.
  • Business Quant data shows Receivables Refunds for RDY at $32.7 million in Q1 2023, $53.7 million in Q1 2022, and $37.6 million in Q1 2021.